AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
15 nov. 2023 07h30 HE
|
AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
09 nov. 2023 08h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present...
Potential COVID Spike Protein Detoxification Regime Discussed in Journal of American Physicians and Surgeons (AAPS)
31 août 2023 14h29 HE
|
Association of American Physicians and Surgeons
TUCSON, Ariz., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Disabling post-COVID symptoms (“long COVID”) and vaccine injury syndromes are increasingly prevalent, and there is no currently accepted treatment...
Ways to Counteract COVID Spike Protein Discussed in Journal of American Physicians and Surgeons (AAPS)
30 août 2023 11h28 HE
|
Association of American Physicians and Surgeons
TUCSON, Ariz., Aug. 30, 2023 (GLOBE NEWSWIRE) -- The SARS-CoV-2 spike protein found in cells and tissues after COVID-19 respiratory illness and COVID-19 vaccination, which is thought to account for...
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
15 août 2023 06h45 HE
|
AIM ImmunoTech Inc.
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 – Company to host conference call and...
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
09 août 2023 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss...
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
08 août 2023 08h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
SSA’s New Guide: A Positive Step For Long COVID Sufferers, Allsup Ready To Assist With SSDI Claims
31 juil. 2023 16h49 HE
|
Allsup
Belleville, Illinois, July 31, 2023 (GLOBE NEWSWIRE) -- The Social Security Administration (SSA) has issued new guidance for long COVID sufferers. The guide offers a clearer picture as to how this...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
10 juil. 2023 08h05 HE
|
AIM ImmunoTech Inc.
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...